Oligodendroglioma Market Insights, Size, Pipeline Review, H1 2016 by Radiant Insights Summary Global Markets Direct's, ‘Oligodendroglioma - Pipeline Review, H1 2016', provides an overview of the Oligodendroglioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Oligodendroglioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. Browse Ongoing Reports @ http://www.radiantinsights.com/research/oligodendroglioma-pipelinereview-h1-2016 Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Oligodendroglioma - The report reviews pipeline therapeutics for Oligodendroglioma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Oligodendroglioma therapeutics and enlists all their major and minor projects - The report assesses Oligodendroglioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Oligodendroglioma Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Oligodendroglioma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Oligodendroglioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse More Categories @ http://www.radiantinsights.com/catalogs Table of Content Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Oligodendroglioma Overview 8 Therapeutics Development 9 Pipeline Products for Oligodendroglioma - Overview 9 Pipeline Products for Oligodendroglioma - Comparative Analysis 10 Oligodendroglioma - Therapeutics under Development by Companies 11 Oligodendroglioma - Therapeutics under Investigation by Universities/Institutes 12 Oligodendroglioma - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Oligodendroglioma - Products under Development by Companies 15 Oligodendroglioma - Products under Investigation by Universities/Institutes 16 Oligodendroglioma - Companies Involved in Therapeutics Development 17 Axelar AB 17 Boehringer Ingelheim GmbH 18 Bristol-Myers Squibb Company 19 Cavion LLC 20 Celgene Corporation 21 Celldex Therapeutics, Inc. 22 e-Therapeutics Plc 23 F. Hoffmann-La Roche Ltd. 24 Millennium Pharmaceuticals, Inc. 25 Novartis AG 26 Pfizer Inc. 27 Tocagen Inc. 28 Oligodendroglioma - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Combination Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Browse Ongoing Reports @ http://www.radiantinsights.com/research/oligodendroglioma-pipelinereview-h1-2016 About Us: Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. Contact Details: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc 28 2nd Street, Suite 3036 San Francisco, CA 94105 United States Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Website: http://www.radiantinsights.com/ Email: [email protected] Visit our Blog: http://chemicalsandmaterialsri.blogspot.com/

The report provides comprehensive information on the therapeutics under development for Oligodendroglioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Visit Us @ http://www.radiantinsights.com/research/oligodendroglioma-pipeline-review-h1-2016